diabetes and more
53.0K views | +2 today
Follow
 
Scooped by Ellen H Ullman, MSW
onto diabetes and more
Scoop.it!

First-Ever National Neuropathy Patient Registry Aims to Accelerate Research for Neurological Epidemic Impacting Millions

he Neuropathy Association and ResearchMatch research registry collaboration kicks off Neuropathy Awareness Week, which also includes Niagara Falls and other landmark lightings across the U.S. and Canada.
New York, NY (PRWEB) May 12, 2014
The Neuropathy Association and ResearchMatch announce they are collaborating to launch a patient registry to improve and expedite neuropathy research. The Neuropathy Association is a national non-profit patient advocacy organization dedicated to bringing help, hope and healing to people with various forms of neuropathy; ResearchMatch is the first nationwide, non-profit, volunteer, research recruitment platform for all health conditions. According to Kathleen Edson, community engagement manager at ResearchMatch, "The registry collaboration aims to bring together two groups of people who are searching for each other: people who are trying to find neuropathy research studies, and researchers who are looking for people to participate in their studies."
ResearchMatch’s free, secure, online registry has been developed by major academic institutions across the U.S. to engage the general public in today’s ethical, expedited research. This innovative collaboration with The Neuropathy Association establishes a dedicated nationally accessible registry for neuropathy that provides a voice for all neuropathy patients in the research process. Volunteers who register and indicate “neuropathy” as one of their conditions will be prompted to answer additional questions about their condition to better enhance the precision and prescreening process for matching volunteers with research teams who are studying all forms of peripheral neuropathy.
A free informational webinar explaining the registry will be held on Wednesday, May 21, from 7:00- 8:00 pm Eastern followed by a half hour question and answer session on The Neuropathy Association’s Facebook page. To register for the webinar, please visit https://www1.gotomeeting.com/register/955787529. To learn more about the registry and/or to register, please visit http://www.researchmatch.org.
Peripheral neuropathy, or “peripheral nerve damage,” impacts well over 20 million Americans (at least 1 in 15), making it one of the most common chronic diseases and a leading cause of adult disability. Neuropathy disrupts the body’s ability to communicate with its muscles, organs, and tissues. Symptoms can include numbness, tingling, weakness, and pain often beginning in the hands and feet. With early diagnosis, it can often be controlled and quality of life restored. If ignored, symptoms can intensify to loss of sensation, weakness, unremitting pain, and/or disability. Even though neuropathy is at epidemic proportions in the U.S. and abroad, it is often misunderstood, mis- and under-diagnosed, as well as inadequately treated. Limited research opportunities and limited research funding have limited the scope of treatment and curative possibilities for specific neuropathy and neuropathic pain conditions.
“Patients and researchers alike are frustrated with the slow progress being made with neuropathy research. Patients feel disenfranchised from the current clinical trial process because they are still unable connect with the research and researchers addressing their specific health issues; researchers are also finding it challenging to identify qualified research participants. Harnessing the power of today’s on-line technologies, ResearchMatch’s unique, elegant and easy-to-use platform—already accessible to all National Institutes of Health (NIH)-funded researchers as well as the majority of leading researchers across the U.S.— empowers patients to self-identify for research studies and enables researchers to match their work with the types of study participants they seek,” shares Tina Tockarshewsky, president and CEO, The Neuropathy Association.
“A significant factor delaying the development of new treatments is the recruitment and retention of clinical research study participants—both patients as well as healthy volunteers. We’re working proactively with researchers and patients to drive awareness for on-going clinical research study opportunities and to help with recruitment efforts. This collaboration with ResearchMatch is a critical addition to our toolkit and to our overall efforts to better understand neuropathy and bring forth new treatments and cures,” notes Natacha T. Pires, MBBS, director of medical and public affairs at The Neuropathy Association.
"This registry increases the ability to bring a wider scope of volunteers to a broader range of researchers who are working on the spectrum of challenges impacting neuropathy patients," observes Dr. Thomas Brannagan, The Neuropathy Association's medical advisor. "Often studies are stalled by difficulty with recruitment and delays. By increasing the likelihood of matching candidates for study recruitment, we increase the probability that more neuropathy research can move forward quickly."
Of the over 100 known types of neuropathy, diabetic neuropathy represents over a third of all neuropathies, making diabetes the leading cause. A third of neuropathies are “idiopathic” (unknown cause). Other neuropathies include autoimmune-related, hereditary, cancer or chemotherapy-related, entrapment or trauma-related, and neuropathies related to causes such as toxin-induced, nutritional deficiencies, gastro-intestinal disorders, metabolic diseases, or infectious diseases (including Lyme and HIV/AIDS).
This patient registry launch kicks off Neuropathy Awareness Week, May 12-16, 2014. This tenth annual event was initiated by The Neuropathy Association to change perceptions of and promote prevention of this progressive, chronic, and often extremely painful neurological disease and growing national epidemic. Working together with advocates across the U.S. and abroad, The Neuropathy Association and its community of patients, their loved ones, caregivers, healthcare professionals, and industry partners are pleased to announce the following events occurring during and in tandem with Neuropathy Awareness Week:

    PECO Building Lighting, Philadelphia, PA (May 11)
    Niagara Falls Illumination-Canadian and American Falls (May 14)
    SunTrust Financial Center Tower Lighting, Tampa, FL (May 15-16)
    Zakim Bridge Lighting, Boston, MA (May 20)
    Indy 500 Jumbo-trons Feature Neuropathy Public Service Announcement (PSA), Indianapolis, IN (May 23-25)
About The Neuropathy Association
Founded in 1995, The Neuropathy Association is the leading national nonprofit organization providing neuropathy patient support, education, advocacy, and the promotion of research into the causes of and cures for peripheral neuropathies through its nationwide network of members, regional chapters, 15 medical Centers of Excellence, and 150 patient support groups.
About ResearchMatch
ResearchMatch is a national partnership created as a centralized, web-based recruitment registry, connecting individuals who are interested in participating in research with researchers nationwide. The site is a funded in part by the National Institutes of Health (NIH) and Clinical and Translational Science Award (CTSA) program grants. The CTSA program is led by the NIH’s National Center for Advancing Translational Science (NCATS). The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH.


For the original version on PRWeb visit: http://www.prweb.com/releases/2014NeuropathyAwarenessWk/ResearchRegistry/prweb11841989.htm

more...
No comment yet.
diabetes and more
Important news for those concerned with all types of diabetes, associated autoimmune diseases, & health
Your new post is loading...
Your new post is loading...
Scooped by Ellen H Ullman, MSW
Scoop.it!

JDRF - New Research Advisory Committee formed to support people with type 1 diabetes

JDRF - New Research Advisory Committee formed to support people with type 1 diabetes | diabetes and more | Scoop.it
JDRF, the leading global organization funding type 1 diabetes (T1D) research, announced today the formation of a new external Research Advisory Committee (RAC) comprised of individuals internationally renowned for their expertise in research as well as the care and treatment of those with T1D.
Ellen H Ullman, MSW's insight:

"to bring the greatest good for the largest number of people in the shortest amount of time."  - The majority of the people worldwide with t1 diabetes will not benefit from the artificial pancreas - they need a biological cure.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Potential diabetes treatment advances

Potential diabetes treatment advances | diabetes and more | Scoop.it
Device shields beta cells from immune system attack | Researchers at MIT’s David H. Koch Institute for Integrative Cancer Research, in collaboration with scientists at the Harvard Stem Cell Institute and several other institutions, have developed an implantable device that in mice shielded insulin-producing beta cells from immune system attack for six months — a substantial proportion of life span.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Engineered micro-pancreas helps transplanted islet cells to live longer

Engineered micro-pancreas helps transplanted islet cells to live longer | diabetes and more | Scoop.it
A newly-developed micro-pancreas can prevent transplanted islet cells from failing, potentially overcoming one of the biggest problems with islet cell transplantation for people with type 1 diabetes. The platform, known as the engineered micro-pancreas (EMP), is developed by Israeli biotech company Betalin Therapeutics. It solves several of the difficulties associated with islet cell transplantation. Researchers know how to transplant islet cells to people with type 1 diabetes, and they know how to make those cells work. What they don't know is how to stop those cells from failing. Half of islet cell transplant patients are back on insulin injections with a year; 90 per cent within five years.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

FULL TEXT - A child with type 1 diabetes mellitus (T1DM) successfully treated with the Paleolithic ketogenic diet: A 19-month insulin freedom - International Journal of Case Reports and Images (IJCRI)

FULL TEXT - A child with type 1 diabetes mellitus (T1DM) successfully treated with the Paleolithic ketogenic diet: A 19-month insulin freedom - International Journal of Case Reports and Images (IJCRI) | diabetes and more | Scoop.it
Introduction: Currently type 1 diabetes mellitus (T1DM) is treated with insulin and a high carbohydrate diet. In the literature, however, there are studies indicating that low carbohydrate diets may be beneficial in reducing hypoglycemic episodes as well as the need for insulin. Previously we reported a case of a 19-year-old T1DM patient who was successfully treated with a modified version of the ketogenic diet we refer to as the Paleolithic ketogenic diet. Case Report: Here we provide a case study of a 9-year-old child with T1DM who initially was on an insulin regime with high carbohydrate diet then was put on the Paleolithic ketogenic diet. Following dietary shift glucose levels normalized and he was able to discontinue insulin. No hypoglycemic episodes occurred on the diet and several other benefits were achieved including improved physical fitness, reduction of upper respiratory tract infections and eczema. Currently he is on the diet for 19 months. Conclusion: Adopting the Paleolithic ketogenic diet ensured normoglycemia without the use of external insulin. The diet was sustainable on the long-term. Neither complications nor side-effects emerged on the diet.
Ellen H Ullman, MSW's insight:

SHARING WITH AN ABUNDANCE OF CAUTION.  THERE IS NOTHING HEALTHFUL ABOUT THIS DIET IN A 9 YEAR OLD GROWING CHILD IMO.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Two Big Wins For A UConn Medical Device Startup- Implantable Sensor - size of a grain of rice

Two Big Wins For A UConn Medical Device Startup- Implantable Sensor - size of a grain of rice | diabetes and more | Scoop.it
STORRS — It's been a whirlwind fall season at Biorasis, a startup biomedical company at UConn.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Artificial Pancreas Could Be Operated by a Smartphone

Artificial Pancreas Could Be Operated by a Smartphone | diabetes and more | Scoop.it
RT @SamISureAm: Managing #Diabetes could be much easier with a smartphone-operated #ArtificialPancreas
https://t.co/lhUqZNMI1Y https://t.c
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Researchers Coax Leftover Pancreatic Cells to Morph Into Insulin-Producing Cells - EndocrineWeb

Researchers Coax Leftover Pancreatic Cells to Morph Into Insulin-Producing Cells - EndocrineWeb | diabetes and more | Scoop.it
Using a growth factor produced naturally by the human body – and used in spinal-fusion surgeries – scientists from the Diabetes Research Institute (DRI) at the University of Miami Miller School of Medicine have coaxed “leftover” cells from the...
Ellen H Ullman, MSW's insight:

Rodent studies.  Next step "animal studies".  Let's hope HUMANS will someday benefit from this research.

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

“You Can’t Eat That!” – the effect of words on diabetes, research by Jane K. Dickinson

Jane K. Dickinson is a nurse and Certified Diabetes Educator, who has been living with type 1 diabetes for 40 years. In 1993 Jane gave her first talk on the ...
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Immunotherapy for type 1 diabetes deemed safe in first US trial

Immunotherapy for type 1 diabetes deemed safe in first US trial | diabetes and more | Scoop.it
In the first U.S. safety trial of a new form of immunotherapy for type 1 diabetes (T1D), led by UC San Francisco scientists and physicians, patients experienced no serious adverse reactions after receiving infusions of as many as 2.6 billion cells that had been specially selected to protect the body's ability to produce insulin.
Ellen H Ullman, MSW's insight:

I'd like to see the data!  Your thoughts? 

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Oral Insulin Capsule to Replace Injections - NOT READY FOR PRIME TIME!

Oral Insulin Capsule to Replace Injections - NOT READY FOR PRIME TIME! | diabetes and more | Scoop.it
A way to deliver insulin in a capsule that can be taken orally has been developed with the hope that it can replace injections for people with diabetes.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Scientists create insulin-producing cells that may treat diabetes | EurekAlert! Science News

Scientists create insulin-producing cells that may treat diabetes | EurekAlert! Science News | diabetes and more | Scoop.it
A new technique to produce cells with insulin-secretion capabilities has been developed, according to research presented today at the 54th Annual European Society for Paediatric Endocrinology Meeting. The technique could be further developed to be used in the transplantation for patients with type 1 diabetes.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Insulin-Producing Pancreatic Cells Could Be The Next Big Thing In Cure Of Diabetics

Insulin-Producing Pancreatic Cells Could Be The Next Big Thing In Cure Of Diabetics | diabetes and more | Scoop.it
A team of scientists has discovered cells in the human body that could potentially be used to harness insulin to cure diabetics.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Home Use of an Artificial Beta Cell in Type 1 Diabetes — NEJM

Original Article from The New England Journal of Medicine — Home Use of an Artificial Beta Cell in Type 1 Diabetes
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Scott's Web Log: Just Who Is JDRF Therapeutic Ventures, LLC? Why is it such a secret?

Scott's Web Log: Just Who Is JDRF Therapeutic Ventures, LLC? Why is it such a secret? | diabetes and more | Scoop.it
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Beyond Fitness Trackers At CES: Tiny Wearable Biosensor Continuously Monitors Your Body Chemistry

Beyond Fitness Trackers At CES: Tiny Wearable Biosensor Continuously Monitors Your Body Chemistry | diabetes and more | Scoop.it
Forbes Welcome page -- Forbes is a global media company, focusing on business, investing, technology, entrepreneurship, leadership, and lifestyle.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

7 New Diabetes Products to Look for in 2016

7 New Diabetes Products to Look for in 2016 | diabetes and more | Scoop.it
Looking ahead to 2016, we’re optimistic about these seven diabetes products potentially hitting the market in the next 12 months.
more...
Scooped by Ellen H Ullman, MSW
Scoop.it!

Small cap Nemaura raises $10M, starts JV for EU launch of patch-based glucose monitor

Small cap Nemaura raises $10M, starts JV for EU launch of patch-based glucose monitor | diabetes and more | Scoop.it
Nemaura Medical stealthily listed on the Nasdaq OTC market late last year. That followed a corporate restructuring in late 2013. All this is in the name of developing a novel continuous glucose monitoring system that includes a disposable patch, a watch and a smartphone app--that the company has dubbed SugarBeat.
Ellen H Ullman, MSW's insight:

Hopefully it's better than the old Glucowatch!

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Tweet from @Diabetes_DRI

Tweet from @Diabetes_DRI | diabetes and more | Scoop.it
What do human islets have in common with animal islets? See answer here: instagram.com/p/-319ghFBpX/ #t1d #science pic.twitter.com/gaKzSQG6xu
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Current Research into Cures for Type-1 Diabetes via Joshua Levy

more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Orgenesis and Biosequel Enter Collaboration Agreement for Conducting Clinical ... - CNNMoney

Orgenesis and Biosequel Enter Collaboration Agreement for Conducting Clinical ... - CNNMoney | diabetes and more | Scoop.it
Orgenesis and Biosequel Enter Collaboration Agreement for Conducting Clinical ...
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

INGAP IS BACK? Landmark clinical trial of a novel combination treatment for type 1 diabetes

INGAP IS BACK?  Landmark clinical trial of a novel combination treatment for type 1 diabetes | diabetes and more | Scoop.it
Investigators at Montreal's Lady Davis Institute at the Jewish General Hospital and McGill University Health Centre have announced the start of a landmark clinical study aimed at restoring normal insulin secretion in people with longstanding type 1 diabetes. The treatment combines INGAP Peptide (ExsulinTM), which stimulates growth of the insulin secreting islets, and ustekinumab (SteleraTM), a drug approved for the treatment of psoriasis.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

The Doctor on a Quest to Save Our Medical Devices From Hackers

The Doctor on a Quest to Save Our Medical Devices From Hackers | diabetes and more | Scoop.it
Dr. David Klonoff is spearheading an effort to eliminate dangerous security holes in insulin pumps, which could help secure other medical devices as well.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

Richard Vaughn Interviewed by Daniele Hargenrader - Unleash Your Inner Diabetes Dominator, Episode 25 - The Diabetes Dominator™

Richard Vaughn Interviewed by Daniele Hargenrader - Unleash Your Inner Diabetes Dominator, Episode 25 - The Diabetes Dominator™ | diabetes and more | Scoop.it
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

4-drug mixture reverses Type 1 diabetes in mice

4-drug mixture reverses Type 1 diabetes in mice | diabetes and more | Scoop.it
Call it the scientist’s version of happy hour: A new, four-drug cocktail has shown a novel ability to reverse established Type 1 diabetes in some mice, University of Florida Health researchers have found.
more...
No comment yet.
Scooped by Ellen H Ullman, MSW
Scoop.it!

EASD Virtual Meeting - Prof. Steven Russel The Bionic Pancreas: When will the dream come true?

EASD Virtual Meeting - Prof. Steven Russel The Bionic Pancreas: When will the dream come true? | diabetes and more | Scoop.it
Randomized cross-over design (11 days bionic pancreas, 11 days usual care)Subjects work or study on one of four campusesMGH, UNC Chapel Hill, Stanford, UMass Medical Center10 subjects per site (40 total)Normal daily routine, no restrictions on diet or exerciseRemote monitoring of alarms in BP, call subject if not response to alarms
Ellen H Ullman, MSW's insight:

Thank you Joshua Levy for sharing this via Twitter

more...
No comment yet.